Research across Vasculitis
Related studies from across the Vasculitis family.
IL-5/IL-5Rα blockade provides clinically validated benefit in EGPA but requires phenotype-specific evidence for other conditions
Targeting Eosinophils Shows Promise for Specific Autoimmune Conditions
This narrative review explores the role of eosinophils and IL-5/IL-5Rα and IL-4Rα blockade in various autoimmune diseases. The authors concl…
New research highlights how targeting specific immune cells like eosinophils can help manage certain inflammatory and autoimmune diseases.
Systematic review evaluates anti-IL-5 and anti-IL-5Rα biologics for eosinophilic respiratory and systemic diseases
New Asthma Drugs Target the Real Troublemakers Hiding in Your Lungs
This systematic review examined the use of anti-IL-5 and anti-IL-5Rα biologics in patients with severe eosinophilic asthma, chronic rhinosin…
New asthma drugs target the specific immune cells causing swelling and mucus in severe asthma, nasal polyps, and rare eosinophil diseases.
Expert review outlines diagnostic and therapeutic management strategies for eosinophilic granulomatosis with polyangiitis
Rare Lung and Blood Disease Gets a Smarter Treatment Map
This expert review addresses the management of patients with eosinophilic granulomatosis with polyangiitis (EGPA), focusing on glucocorticoi…
A new expert roadmap shifts treatment for rare EGPA disease from steroids to targeted biologic drugs for patients with stubborn asthma and o…
Questions about Microscopic Polyangiitis
How does the mortality risk for microscopic polyangiitis compare to granulomatosis with polyangiitis?
Microscopic polyangiitis (MPA) generally carries a higher mortality risk than granulomatosis with polyangiitis (GPA), with studies showing poorer survival and higher hazard ratios for death in MPA patients.
Full answer →